'Report Predicts World Antibacterial Drugs Market Will Reach $43.8bn In 2016' Says visiongain Report

LONDON, November 29, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/724/Antibacterial-Drugs-World-Market-Prospects-2012-2022

A new report by visiongain, a London-based business information company, predicts that world revenues for antibacterial drugs will reach $43.81bn in 2016. Between 2010 and 2022, the global market will expand with a CAGR of 2.2%. Those findings appear in Antibacterial Drugs: World Market Prospects 2012-2022, published in November 2011.

Visiongain forecasts that cephalosporins will remain the largest sector of the market throughout the forecast period, with revenues growing to $11.67bn by 2016. The fastest growing class of antibacterial drug will be the carbapenems, revenues for which will grow with a CAGR of 3% between 2010 and 2022. Increased uptake in place of other drug classes will drive this growth, as will the class's low susceptibility to bacterial resistance.

The visiongain pharmaceutical industry analyst, said: "The market will rely on strong uptake of new drugs, such as Ortho-McNeil/Shionogi's Doribax, to drive growth to 2022. However, newer drugs will find it increasingly difficult to reach blockbuster status, given the high level of generic competition expected in the market this decade."

This study forecasts the future of the leading five classes of antibacterial drug, as well as the top 20 individual drugs, showing revenue forecasts to 2022. In 2010, only two blockbusters existed in the antibacterial drugs market - Levaquin and Zyvox - and both products are expected to have revenues below $1bn by 2017.

Leading national markets are also analysed and discussed in the report, with market forecasts provided. In 2010, China was the world's second largest market for antibacterial drugs. Antibiotics apparently accounted for 70% of all prescriptions there in 2008. That market will continue to grow more rapidly than those of other leading countries this decade, despite rules introduced in 2011 to limit antibiotic drug prescription.

Urgent medical needs exist in the antibacterial drugs industry and market, as a result of bacterial resistance to antibiotics. Nosocomial infections are a major burden on healthcare budgets in developed and developing countries. With a weak R&D pipeline - particularly against Gram-negative infections - expansion of the antibacterial drugs market will slow over the coming 10 years. Antibacterial Drugs: World Market Prospects 2012-2022 adds to visiongain's range of analytical research covering important therapeutic areas of the pharmaceutical industry.

To view sample pages please click on:

http://www.visiongain.com/Report/724/Antibacterial-Drugs-World-Market-Prospects-2012-2022

Please contact Sara Peerun for an exec summary:

Email: sara.peerun@visiongainglobal.com

Tel: +44-(0)20-7336-6100

Notes for Editors

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

1. Executive Summary
1.1 Antibacterial Drugs: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. An Introduction to Bacteria, Bacterial Infections and Antibacterial Drugs
2.1 Bacteria and Bacterial Infections
2.1.1 Bacteria
2.1.2 Clinically Important Bacteria
2.1.3 Bacterial Infections
2.1.3.1 Bacteria's Infectious Activity
2.2 Antibacterial Drugs
2.2.1 A History of Antibacterial Drugs
2.2.1.1 Penicillin
2.2.1.2 Other Key Steps in the History of Antibacterial Drugs
2.2.2 Mechanisms of Action for Antibacterial Drugs

3. The Antibacterial Drugs Market 2012-2022
3.1 The Antibacterial Drugs Market 2010-2011
3.2 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
3.2.1 Generic Competition
3.2.2 Prescribing Antibacterial Drugs
3.2.3 Bacterial Resistance
3.2.4 R&D Pipeline Will Restrain Growth?
3.3 Cephalosporins Submarket 2010-2011
3.3.1 Cephalosporins Submarket: Revenue Forecast 2012-2022
3.4 Penicillin Submarket 2010-2011
3.4.1 Penicillins Submarket: Revenue Forecast 2012-2022
3.5 Fluoroquinolone Submarket 2010-2011
3.5.1 Fluoroquinolones are Linked with Side Effects
3.5.2 Fluoroquinolone Pipeline 2011
3.5.3 Fluoroquinolone Submarket: Revenue Forecast 2012-2022
3.6 Macrolide Submarket 2010-2011
3.6.1 Dificid: A New Macrolide
3.6.2 Macrolide Submarket: Revenue Forecast 2012-2022
3.7 Carbapenems Submarket 2010-2011
3.7.1 Doribax (Doripenem, Ortho-McNeil/Shionogi)
3.7.2 Carbapenems Submarket: Revenue Forecast 2012-2022
3.8 Other Antibacterial Drugs Submarket 2010-2011
3.8.1 Vibativ
3.8.2 Other Antibacterial Drugs Submarket: Revenue Forecast 2012-2022

4. Leading Antibacterial Drugs: Market Prospects to 2022
4.1 Leading Antibacterial Drugs Overview
4.2 Levaquin
4.2.1 Levaquin: Revenue Forecast 2012-2022
4.3 Zyvox
4.3.1 Zyvox: Revenue Forecast 2012-2022
4.4 Avelox
4.4.1 Avelox: Revenue Forecast 2012-2022
4.5 Augmentin
4.5.1 Augmentin: Revenue Forecast 2012-2022
4.6 Zosyn
4.6.1 Zosyn: Revenue Forecast 2012-2022
4.7 Merrem
4.7.1 Merrem: Revenue Forecast 2012-2022
4.8 Cubicin
4.8.1 Cubicin: US Revenue Forecast 2012-2022
4.9 Primaxin
4.9.1 Primaxin: Revenue Forecast 2012-2022
4.10 Biaxin
4.11 Cravit
4.11.1 Cravit: Revenue Forecast 2012-2022
4.12 Zithromax
4.13 Invanz
4.13.1 Invanz: Revenue Forecast 2012-2022
4.14 Cipro
4.15 Tygacil
4.15.1 Tygacil: Revenue Forecast 2012-2022
4.16 Rocephin
4.16.1 Rocephin: Revenue Forecast 2012-2022
4.17 Zinnat
4.18 Flomox
4.19 Unasyn
4.20 Dalacin C
4.21 Meiact

5. Leading National Antibacterial Drug Markets 2012-2022
5.1 Leading National Markets 2010-2011
5.2 Leading National Markets: Revenue Forecasts 2012-2022
5.3 The European Market: Revenue Forecasts 2012-2022
5.4 The US: Revenues 2012-2022
5.5 China: Revenues 2012-2022
5.6 Japan: Revenues 2012-2022
5.7 India: Revenues 2012-2022
5.8 Brazil: Revenues 2012-2022

6. Antibacterial Drugs R&D Pipeline in 2011
6.1 Zinforo (Ceftaroline, AstraZeneca/Forest Laboratories)
6.2 Ceftobiprole (Basilea Pharmaceutica)
6.3 Restanza (Cethromycin, Advanced Life Sciences): Any Future Development?
6.4 Dalbavancin (Durata Therapeutics)
6.5 Nuvocid (Oritavancin, The Medicines Company)
6.6 TR-701 (Tedizolid, Trius Therapeutics)
6.7 CAZ104 (Ceftazidime/Avibactam, AstraZeneca/Forest Laboratories)
6.7.1 CEF104 (Ceftaroline/Avibactam, AstraZeneca/Forest Laboratories)
6.8 CXA-201 (Cubist)
6.9 NKTR-061 (Amikacin Inhalation, Bayer/Nektar Therapeutics)
6.10 Ramoplanin (Nanotherapeutics)
6.11 Radezolid (Rib-X Pharmaceuticals)

7. Antibacterial Drugs: Industry Trends 2012-2022
7.1 Strengths and Weaknesses in the Antibacterial Drugs Market 2011
7.2 Opportunities and Threats in the Antibacterial Drugs Market 2012-2022
7.3 Late-Stage Pipeline Therapies
7.3.1 Governmental Incentives
7.4 New Strategies
7.4.1. Monoclonal Antibodies
7.4.2 Inhaled Antibiotics for Hospital-Acquired Pneumonia
7.5 Bacterial Resistance: An Opportunity and a Threat
7.5.1 Emerging Resistance
7.5.2 Restricting Drug Use
7.6 The Challenge of Non-Inferiority Trials
7.7 Improved Regulatory Guidance
7.8 Lifecycle Management
7.9 Hospital-Acquired Infections
7.9.1 Treating Hospital-Acquired Infections
7.9.2 Preventing Hospital-Acquired Infections
7.9.3 Hospital Hygiene
7.9.4 Tracking Infections
7.9.5 Advances in Hospital Equipment
7.9.5.1 Copper Kills Bacteria

8. Research Interviews8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica
8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica
8.1.1 Basilea Pharmaceutica
8.1.2 Antibacterial Research This Decade
8.1.3 Challenges in Developing Treatments for Gram-Negative Bacteria
8.1.4 Overcoming Drug Resistance
8.1.5 New Targets for Antibacterial Drug Development
8.2 Dr Michael Rudolf, CSO, Kenta Biotech
8.2.1 Kenta Biotech
8.2.2 Monoclonal Antibodies for Bacterial Infections
8.2.3 Challenges in Developing Treatments for Gram-Negative Bacteria
8.2.4 Unmet Needs in the Antibacterial Drugs Market

9. Conclusions from Our Study
9.1 Antibacterial Drugs Market 2012-2022
9.1.1 Leading Product Performance 2012-2022
9.2 The R&D Pipeline: Outlook for the Future
9.3 Bacterial Resistance: a Rising Challenge

Other Content
Glossary: Clinical Bacteriology


Companies Listed

Abbott Laboratories
Acino
Adimab
Advanced Life Sciences
Agência Nacional de Vigilância Sanitária (Anvisa) [Brazil]
Aisling Capital
Alliance for the Prudent Use of Antibacterials (APUA) [US]
Alopexx Pharmaceuticals
Andrx (now part of Watson Pharmaceuticals)
APP Pharmaceuticals (a subsidiary of Fresenius Kabi)
Arsanis
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals (now part of Teva)
Basilea Pharmaceutica
Bayer
Bioquell
C&O Pharmaceutical Technology (Holdings)
Calixa Therapeutics (now part of Cubist Pharmaceuticals)
Canaan Partners
Cempra
Centers for Disease Control and Prevention (CDC) [US]
Centers for Medicare and Medicaid Services (CMS) [US]
Cipla
Copper Development Association [US]
Cornerstone Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dr. Reddy's Laboratories
Duke University [US]
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP)
European Medicines Agency (EMA)
FDA Anti-Infective Drugs Advisory Committee (AIDAC) [US]
Food and Drug Administration (FDA) [US]
Forest Laboratories
Fresenius Kabi Pharmaceuticals
Furiex Pharmaceuticals
Future Path Medical
Gilead Sciences
Glenmark Generics
GSK
Harvard Medical School
Healthcare Infection Control Practices Advisory Committee (HICPAC) [US]
Hikma Farmaceutica
Hospira
Innocell
Insmed
Itochu Chemical Frontier
J&J
Janssen Pharmaceutica (a subsidiary of J&J)
Japan Patent Office (JPO)
KaloBios Pharmaceuticals
Kenta Biotech
King's College London
Lederle Laboratories (acquired by Wyeth, now part of Pfizer)
Lupin Pharmaceuticals
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Meiji Seika Kaisha
Merck & Co.
Michigan State University
Ministry of Health and Family Welfare [India]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mpex Pharmaceuticals
Mylan
Nanotherapeutics
National Health Service (NHS) [UK]
Nektar Therapeutics
New Leaf Venture Partners
Novartis
Novexel
Optimer Pharmaceuticals
Orchid Chemicals and Pharmaceuticals
Ortho-McNeil Pharmaceuticals (a subsidiary of J&J)
Oscient Pharmaceuticals
Paratek Pharmaceuticals
Parke-Davis (now part of Pfizer)
Peking University
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pharmacia (now part of Pfizer)
Pliva (now part of Teva)
RaQualia Pharma
Rib-X Pharmaceuticals
Roche
Sandoz
Sanofi
Sanofi Pasteur (part of Sanofi)
Sawai Pharmaceutical
Schering-Plough (now part of Merck & Co)
Shionogi
St Thomas' Hospital
Strides Arcolab
Sumitomo Pharmaceuticals (now part of Dainippon Sumitomo)
Takeda Pharmaceutical Company
TAP Holdings
Targanta Therapeutics (now part of The Medicines Company)
Teva Pharmaceuticals
The Medicines Company
Theravance
Trius Therapeutics
University of Birmingham [UK]
University of Pennsylvania
US Department of Defense
Vicuron Pharmaceuticals (now part of Durata Therapeutics)
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Wyeth (now part of Pfizer)

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)-207-336-6100